Global Blood Therapeutics, Inc. (NASDAQ:GBT) went up by 6.44% from its latest closing price compared to the recent 1-year high of $87.54. The company’s stock price has collected -4.81% of loss in the last five trading sessions. Press Release reported on 09/09/20 that GBT and Sickle Cell Disease Association of America to Host 9th Annual Sickle Cell Disease (SCD) Therapeutics Conference
Is It Worth Investing in Global Blood Therapeutics, Inc. (NASDAQ :GBT) Right Now?
Plus, the 36-month beta value for GBT is at 1.75. Opinions of the stock are interesting as 14 analysts out of 18 who provided ratings for Global Blood Therapeutics, Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $110.35, which is -$56.16 below the current price. GBT currently public float of 54.43M and currently shorts hold a 16.12% ratio of that float. Today, the average trading volume of GBT was 842.56K shares.
GBT’s Market Performance
GBT stocks went down by -4.81% for the week, with a monthly drop of -9.30% and a quarterly performance of -11.03%, while its annual performance rate touched 3.92%. The volatility ratio for the week stands at 6.31% while the volatility levels for the past 30 days are set at 4.45% for Global Blood Therapeutics, Inc.. The simple moving average for the period of the last 20 days is -8.59% for GBT stocks with a simple moving average of -17.72% for the last 200 days.
Analysts’ Opinion of GBT
Many brokerage firms have already submitted their reports for GBT stocks, with Raymond James repeating the rating for GBT by listing it as a “Outperform.” The predicted price for GBT in the upcoming period, according to Raymond James is $115 based on the research report published on August 25th of the current year 2020.
ROTH Capital, on the other hand, stated in their research note that they expect to see GBT reach a price target of $129. The rating they have provided for GBT stocks is “Buy” according to the report published on July 20th, 2020.
BofA Securities gave a rating of “Buy” to GBT, setting the target price at $92 in the report published on July 13th of the current year.
GBT Trading at -14.65% from the 50-Day Moving Average
After a stumble in the market that brought GBT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.85% of loss for the given period.
Volatility was left at 4.45%, however, over the last 30 days, the volatility rate increased by 6.31%, as shares sank -8.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.20% lower at present.
During the last 5 trading sessions, GBT fell by -4.81%, which changed the moving average for the period of 200-days by -10.84% in comparison to the 20-day moving average, which settled at $61.17. In addition, Global Blood Therapeutics, Inc. saw -29.35% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at GBT starting from CATHERS BRIAN EDWIN, who sold 2,200 shares at the price of $63.77 back on Aug 20. After this action, CATHERS BRIAN EDWIN now owns 5,244 shares of Global Blood Therapeutics, Inc., valued at $140,294 using the latest closing price.
Fink Eric, the Chief Human Resources Officer of Global Blood Therapeutics, Inc., sold 2,454 shares at $69.62 during a trade that took place back on Aug 05, which means that Fink Eric is holding 0 shares at $170,851 based on the most recent closing price.
Stock Fundamentals for GBT
Current profitability levels for the company are sitting at:
- -13737.38 for the present operating margin
- -373.43 for the gross margin
The net margin for Global Blood Therapeutics, Inc. stands at -12654.93. The total capital return value is set at -44.58, while invested capital returns managed to touch -41.12. Equity return is now at value -50.80, with -38.40 for asset returns.
Based on Global Blood Therapeutics, Inc. (GBT), the company’s capital structure generated 25.54 points at debt to equity in total, while total debt to capital is 20.34.
When we switch over and look at the enterprise to sales, we see a ratio of 1,979.98, with the company’s debt to enterprise value settled at 0.04. The receivables turnover for the company is 1.60 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.79.